Our results showed that FAM111B expression was elevated in older patients, higher-grade gliomas (WHO III/IV), IDH-mutated gliomas, gliomas without 1p/19q codeletion, and patients with glioblastomas (Fig. 1E–I). Here, FAM111B is linked to central nervous system cancer.